Introduction: ALZ-801 is a novel, orally available small molecule prodrug of tramiprosate with improved pharmaceutical properties. Tramiprosate was advanced to a ~2,000 patient Phase 3 program which completed in 2007, and was deemed inconclusive by the FDA. Subsequent post-hoc analyses of ApoE4 positive patients (n=599) showed that tramiprosate produced a significant and clinically meaningful improvement [...]